Suzanna Bota

Dr. Suzanna Bota

Auto-generated profile, based on publicly available information

Dr. Suzanna Bota


Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 February 2006 in Revue des Maladies Respiratoires
Verified
Journal Article
Closed access
SLS. Lachkar
S. Lachkar
SBS. Bota
S. Bota
GNG. Nouvet
G. Nouvet
LTL. Thiberville
L. Thiberville

13 May 2024 in Preprints.org
Verified
Preprint
Open access
PDF file
EDEdouard Dantoing
Edouard Dantoing
PDPierre Demontrond
Pierre Demontrond
BLBénédicte Léturgie
Bénédicte Léturgie
HCHubert Curcio
Hubert Curcio
COCharlotte Orsini
Charlotte Orsini
FGFLORIAN GUISIER
FLORIAN GUISIER
Small-cell lung cancer (SCLC) is a cancer with poor prognosis. For relapsed extensive-stage (ES) SCLC, second-line treatment options are scarce. Topotecan was the only approved treatment in this setting until 2020. Since topotecan induces significant toxicities, alternative off-label regimens are being used. This study evaluated real-world efficacy and safety of Paclitaxel Gemcitabine chemotherapy in patients with relapsed ES-SCLC. We retrospectively reviewed data from all consecutive patients with relapsed ES-SCLC who received Paclitaxel Gemcitabine chemotherapy from september 2008 to january 2022 in two centers. Patient characteristics (n=188) were: PS≥2: 24.5%; brain metastasis: 42%; platinum-sensitive disease: 41%. Patients received Paclitaxel Gemcitabine as second- (77%) third (18%) or fourth (6%) line of therapy. Median progression-free and overall survival were 2.1 (95CI 1.8–2.4) and 3.8 (95CI 3.3–4.8) months in the overall population, respectively, with 17% response rate (RR) and 28% disease-control rate. PS, history of brain radiation, platinum-sensitive disease, liver, and adrenal gland metastasis were associated with longer survival in univariate analysis. PS was the only prognostic factor in multivariate analysis, with 21% RR and 4.1 months median DOR in PS 0-1 patients. Paclitaxel Gemcitabine chemotherapy may represent a treatment option in PS0-1 relapsed SCLC.